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Ghrelin, des-acyl ghrelin and other related peptides possess anticonvulsant activities.
Although ghrelin and cognate peptides were shown to physiologically regulate only
the ghrelin receptor, some of them were pharmacologically proved to activate the
peroxisome proliferator-activated receptor gamma (PPARγ) through stimulation of the
scavenger receptor CD36 in macrophages. In our study, we challenged the hypothesis
that PPARγ could be involved in the anticonvulsant effects of EP-80317, a ghrelin
receptor antagonist. For this purpose, we used the PPARγ antagonist GW9662 to
evaluate the modulation of EP-80317 anticonvulsant properties in two different models.
Firstly, the anticonvulsant effects of EP-80317 were studied in rats treated with
pilocarpine to induce status epilepticus (SE). Secondly, the anticonvulsant activity of
EP-80317 was ascertained in the repeated 6-Hz corneal stimulation model in mice.
Behavioral and video electrocorticographic (ECoG) analyses were performed in both
models. We also characterized levels of immunoreactivity for PPARγ in the hippocampus
of 6-Hz corneally stimulated mice. EP-80317 predictably antagonized seizures in both
models. Pretreatment with GW9662 counteracted almost all EP-80317 effects both in
mice and rats. Only the effects of EP-80317 on power spectra of ECoGs recorded
during repeated 6-Hz corneal stimulation were practically unaffected by GW9662
administration. Moreover, GW9662 alone produced a decrease in the latency of tonic-
clonic seizures and accelerated the onset of SE in rats. Finally, in the hippocampus
of mice treated with EP-80317 we found increased levels of PPARγ immunoreactivity.
Overall, these results support the hypothesis that PPARγ is able to modulate seizures
and mediates the anticonvulsant effects of EP-80317.
Keywords: 6-Hz corneal stimulation, EP-80317, ghrelin, peroxisome proliferator-activated receptor gamma,
pilocarpine, status epilepticus, seizure
INTRODUCTION
Ghrelin and des-acyl ghrelin are neuroactive peptides prevalently produced in the stomach by X/A-
like cells in rats, or P/D1 cells in humans (Rindi et al., 2002; Kojima, 2005; Chen et al., 2009). They
regulate very important physiological functions, such as growth hormone secretion, food intake
and metabolism by interacting with hypothalamic neurons (Nakazato et al., 2001). Ghrelin has also
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been investigated for its possible role in regulating neuronal
activity in other brain regions, since its receptor was found
to be expressed out of the hypothalamus and especially in
the hippocampus (Zigman et al., 2006). Interestingly, ghrelin
was demonstrated to play an important role in learning and
memory, cognitive functions in which the hippocampus is
critically involved (Diano et al., 2006; Carlini et al., 2010; Li et al.,
2013). Furthermore, ghrelin was also shown to modulate energy
metabolism in areas other than the hypothalamus, as well as
to be involved in the rewarding system of the brain (Egecioglu
et al., 2010; Skibicka and Dickson, 2011; Skibicka et al., 2011;
Perelló and Zigman, 2012). Overall, these evidences delineate a
variety of physiological roles for ghrelin in the central nervous
system (CNS).
Ghrelin has also been implicated in cerebral diseases.
Specifically, it was shown to afford neuroprotection in models
of cerebral ischemia (Spencer et al., 2013), Parkinson’s disease
(Bayliss and Andrews, 2013), and status epilepticus (SE) (Xu et al.,
2009; Lucchi et al., 2013). Interestingly, this last neuroprotective
effect occurred at a dosage unable to alter the epileptic activity.
However, ghrelin was also found to modulate seizures induced
by several, different approaches (Casillas-Espinosa et al., 2012;
Portelli et al., 2012a; Kovac and Walker, 2013; Clynen et al.,
2014; Curia et al., 2014; Dobolyi et al., 2014). Independent
studies suggested an anticonvulsant activity of ghrelin in
experimental paradigms by which seizures were induced using
pentylenetetrazole (Obay et al., 2007), penicillin (Aslan et al.,
2009), kainic acid (Lee et al., 2010), and pilocarpine (Portelli
et al., 2012b). According to Lee et al. (2010), the anticonvulsant
effects of ghrelin could be related to the interaction of this peptide
with its established receptor. However, the ghrelin receptor
was also demonstrated to possess a proconvulsant activity in
basal condition, whereas the observed anticonvulsant properties
of ghrelin ligands were explained by the induction of ghrelin
receptor internalization (Portelli et al., 2012b).
Other than ghrelin, ghrelin receptor agonists such as hexarelin
(Biagini et al., 2011), capromorelin (Portelli et al., 2012b),
and JMV-1843 (Coppens et al., 2016), the inverse agonists
A778193 and [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P
(Portelli et al., 2012b), as well as the antagonist EP-80317
(Biagini et al., 2011), were all proven to be anticonvulsants.
These data may suggest that all ghrelin receptor ligands
could be able to desensitize neurons expressing the ghrelin
receptor, so to block its proconvulsant activity (Portelli et al.,
2012b). However, this hypothesis could not be supported
in the case of the ghrelin receptor antagonist JMV-2959,
which did not alter the induction of SE by pilocarpine
(Biagini et al., 2011). Alternatively, it could be hypothesized
that the variety of ghrelin-related peptides able to induce
anticonvulsant effects may interact with different receptors that
share a common anticonvulsant activity. Indeed, the existence
of multiple ghrelin receptors has been hypothesized immediately
following the discovery of ghrelin receptor (Davenport et al.,
2005; Müller et al., 2015). In particular, it was evident that
the protective effects exerted by ghrelin, des-acyl ghrelin and
other related peptides in presence of an inflammatory reaction,
especially in the cardiovascular system, were independent of
the ghrelin receptor (Bujold et al., 2009, 2013; Bulgarelli et al.,
2009).
EP-80317 (Haic-D-Mrp-D-Lys-Trp-D-Phe-Lys-NH2) is a
hexapeptide with a primary structure similar to that of hexarelin,
from which it differs for substitutions in the first and third
amino acid residues causing the loss of the growth hormone
(GH)-releasing properties possessed by the original peptide
(Momany et al., 1981). EP-80317 is pharmacologically active
on macrophages, and its activity on these cells was found to be
dependent on activation of the peroxisome proliferator-activated
receptor gamma (PPARγ). However, the ability to activate
PPARγ is also common to ghrelin, des-acyl ghrelin and other
ghrelin-related peptides, as all of them are able to interact with
the CD36 scavenger receptor (Bujold et al., 2009, 2013). In the
CNS, CD36 appears to be expressed prevalently although not
exclusively in microglia (Glezer et al., 2009), whereas PPARγ is
found in neurons of various cerebral regions, including those
known to be involved in the generation and propagation of
seizure activity, such as the hippocampus and the piriform cortex
(Moreno et al., 2004; Warden et al., 2016). For this reason,
we tried to elucidate whether PPARγ could be involved in the
anticonvulsant effects of EP-80317. To this purpose, we designed
experiments in which administration of EP-80317 was challenged
by pretreatment with the PPARγ inhibitor GW9662 (Wong et al.,
2015), in rodents exposed to seizure induction. Additionally, we
characterized the expression of PPARγ in the hippocampus of
mice treated with EP-80317.
MATERIALS AND METHODS
Animals and Treatments
A total of thirty-seven adult male Sprague-Dawley rats (Harlan,
San Pietro al Natisone, Italy), ranging 260–270 g of body weight,
and 66 4-week-old male CD-1 mice (Charles River, Calco, Italy)
were used in this study. All animals were housed in a specific
pathogen-free facility under controlled environment with ad
libitum access to water and food.
EP-80317 was obtained through conventional solid phase
synthesis, dissolved in a physiologic solution and administered
through intraperitoneal (i.p.) injection (330 µg/kg). GW9662
and dimethyl sulfoxide (DMSO) were purchased from Sigma–
Aldrich Chemicals (St. Louis, MO, United States). GW9662
was dissolved in DMSO and diluted with saline and then
administered (2 mg/kg, i.p.) (Rani et al., 2016).
All experiments were in compliance with the European
Directive 2010/63/EU and carried out according to the national
guidelines on animal experimental research of the Italian
Ministry of Health (DM 126/2011 – B and DM 92/2013). The
University of Modena and Reggio Emilia Ethics Committee
approved the study protocol. All efforts were made to refine
procedures to improve the welfare and to reduce the number of
animals that were used.
Experimental Design
For the pilocarpine model, we subdivided rats into four groups
for behavior and video electrocorticographic (ECoG) recordings:
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(i) 10 control rats received saline (1 ml/kg, i.p.), (ii) 10 rats
received EP-80317 alone, (iii) seven rats received GW9662 alone,
and (iv) 10 rats received GW9662 10 min prior to EP-80317.
For the repeated 6-Hz corneal stimulation model, we
considered a number of mice (n = 39) for behavior and
video-ECoG recordings, and the others (n = 27) for
immunohistochemical and immunofluorescence analysis.
In particular, for behavior and video-ECoG recordings, we
subdivided mice into the following groups: (i) nine control mice
received saline (1 ml/kg, i.p.), (ii) 12 mice received EP-80317
alone (330 µg/kg, i.p.), (iii) nine mice received GW9662 alone
(2 mg/kg, i.p.), and (iv) nine mice received GW9662 10 min
prior to EP-80317, both at the already indicated doses. For
immunohistochemical analyses, four control mice were used
to determine basal levels of the investigated marker and were
neither treated nor stimulated. Still, they were handled and
exposed to the same procedure as the others. Twelve were
saline-treated mice, while the other 11 mice received an i.p.
EP-80317 injection. Moreover, these animals were used for
qualitative immunofluorescence experiments but, in this case, we
used only three mice per treatment group.
Pilocarpine Protocol and Behavioral
Analysis
Pilocarpine (Sigma–Aldrich, Milan, Italy) was injected i.p.
(380 mg/kg) to induce SE. The pilocarpine injection was preceded
by methylscopolamine (1 mg/kg, i.p.; Sigma–Aldrich) to prevent
the peripheral effects of cholinergic stimulation (Curia et al.,
2008). EP-80317, GW9662 alone, or saline were injected i.p.
20 min after methylscopolamine and 10 min before pilocarpine.
In the group of rats treated with GW9662 and then with EP-
80317, the first drug was administered 10 min prior to the second
one. In all rats experiencing SE, diazepam (20 mg/kg, i.p.; Hospira
Italia, Naples, Italy) was injected 10 min after the SE onset to
guarantee survival. This procedure stops convulsive seizures,
leaving non-convulsive SE unaltered for hours (Gualtieri et al.,
2012).
Drug-induced responses in rats were observed directly and
graded by blind to treatment expert raters. Seizures were graded
according to a modification of the Racine’s scale (Racine, 1972).
In particular, we considered: (i) non-convulsive seizures, ranked
as stage 1 to stage 3; (ii) convulsive seizures, ranked as stage 4
to stage 5; (iii) SE (stage 6), considered as the stage in which
rats either did not recover normal behavior (i.e., exploration,
grooming, or motor reaction to stimuli) between one seizure and
the other, or in which they displayed continuous shaking for more
than 5 min (Lowenstein, 1999). Rats were sacrificed 72 h after
SE to assess the absence of cerebral lesions caused by electrode
implant, and the presence of injuries developed during the SE.
Corneal Stimulation Protocol and
Behavioral Analysis
Mice were stimulated once and allowed to recover for 72 h
before being stimulated up to four sessions. Corneal stimulation
was performed as previously described (Giordano et al., 2015,
2016). Briefly, a topical eye anesthetic (0.4% oxybuprocaine
hydrochloride eye drops, Novesin, Novartis, Switzerland) was
applied 10 min before stimulation. All mice received the injection
of EP-80317, GW9662, or saline 10 min before each session
of corneal stimulation. When GW9662 preceded EP-80317, it
was administered 20 min before each session. Stimulation (fixed
current intensity of 32 mA, pulse width of 0.2 ms, duration of 3 s,
frequency of 6 Hz) was delivered via corneal electrodes connected
to a stimulator (ECT Unit 5780; Ugo Basile, Comerio, Italy).
Seizure severity was ranked according to the following score:
(i) stunned posture and eye blinking; (ii) head nodding, Straub
tail and repetitive rhythmic movements (stereotypies) such as
chewing; (iii) unilateral or alternating forelimb clonus; (iv)
generalized tonic-clonic convulsions without loss of posture
and rearings; (v) generalized tonic-clonic convulsions with loss
of posture. Seizure scores were first recorded through direct
observation, then reanalyzed on video recordings to quantify the
duration of behavioral changes by an investigator unaware of the
stimulation session. Recovery from seizures was defined as the
reappearance of a normal exploratory behavior.
Electrodes Implantation for
Electrocorticographic (ECoG)
Recordings
For electrode implantation, anesthesia was induced with volatile
isoflurane (4% induction and 1–2% maintenance) in rats, whereas
mice were anesthetized with ketamine (150 µg/g, i.p.)+ xylazine
(10 µg/g, i.p.). After deep anesthesia was reached (assessed by
deep breath, loss of tail and eye reflexes), the skin was shaved,
disinfected with povidone-iodine 10% (Betadine R© skin solution;
Meda Pharma, Milano, Italy), cut and opened to expose the skull.
Guiding holes were drilled and epidural electrodes (stainless
steel Ø = 1 mm; PlasticsOne, Roanoke, VA, United States) were
implanted in frontal (bregma 0 mm, 3.5 mm lateral from midline
in rats and bregma 0 mm, 3 mm lateral from midline in mice) and
occipital cortices (bregma−6.5 mm, 3.5 mm lateral from midline
in rats and bregma−3.5 mm, 3 mm lateral from midline in mice)
of both hemispheres. One electrode was implanted below the
lambda on the midline in all animals and used as a reference.
Electrodes were connected through steel wire to terminal gold
pins (Bilaney Consultant GmbH, Düsseldorf, Germany) inserted
in a plastic pedestal (PlasticsOne) cemented on heads. At the
end of the surgery, gel containing 2.5 g lidocaine chloride,
0.5 g neomycin sulfate and 0.025 g fluocinolone acetonide
(Neuflan R© gel; Molteni Farmaceutici, Scandicci, FI, Italy) was
applied to reduce acute pain and risk of infection. All animals
were monitored until complete recovery from anesthesia, and
were housed in single cages without grids or environmental
enrichments to reduce risk of headset loss.
Video ECoG Recordings
For brain activity recording, animals were placed in cages
with paper filter cover that allowed cable connection between
headset and preamplifiers. Electrical brain activity was digitally
filtered (0.3 Hz high-pass, 500 Hz low-pass), acquired at
1 kHz per channel, and stored on a personal computer after
the mathematical subtraction of traces of recording electrodes
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from trace of reference electrode, using a PowerLab8/30
amplifier connected to 4 BioAmp preamplifiers (ADInstruments;
Dunedin, Otago, New Zealand). Videos were digitally captured
through a camera connected to the computer and synchronized
to the ECoG traces through LabChart 7 PRO internal
trigger. Four days after electrode implantation, all animals
were connected to the recording system and received the
sequence of treatments described above. To facilitate handling
and pharmacological manipulations, recordings were stopped,
animals were temporarily disconnected while being injected and
reconnected soon after. In particular, rats were recorded for
20 min after methylscopolamine administration, 10 min after
EP-80317, GW9662 or saline injection, 10 min after SE onset
and at least 2 h after diazepam administration. Rats that did not
experience SE were recorded for at least 90 min after pilocarpine
injection, until signs of normal behavior (exploring, grooming)
reappeared. Mice were recorded after EP-80317, GW9662 or
saline injection and 6-Hz corneal stimulation, until signs of
normal behavior reappeared.
ECoG Analysis
Electrocorticographic traces were digitally filtered oﬄine (band-
pass: high 50 Hz, low 1 Hz) and manually analyzed using
LabChart 7 PRO software (AD Instruments) by expert raters.
In rats, we measured the duration of each electrographic
seizure, characterized as epileptiform ECoG patterns with trains
of 150–250 ms long spikes with amplitudes at least twice as the
previous 2 s baseline. Seizures occurring within 5 s of each other
were defined as one epileptic event.
In mice, we quantified the ECoG signal of each seizure
performing a power spectral analysis, that described the
distribution of signal power over frequency (Dressler, 2004).
In particular, the power spectrum was obtained by fast Fourier
transformation of the ECoG waveforms (LabChart 7 PRO,
ADInstruments) and used to obtain the mean power spectra
for the experimental groups. The maximum value of power
spectra (peak value) was considered for each mouse. Peak values
of power, recorded from frontal and occipital electrodes, were
evaluated to investigate whether modifications of ictal activity
had occurred from the first to the fourth stimulation.
Immunohistochemistry
Control mice and mice receiving up to one or three sessions of
6-Hz corneal stimulation and treated with saline or EP-80317
were used for tissue analysis. Mice deeply anesthetized with
isoflurane were transcardially perfused with phosphate buffered
saline (PBS, pH 7.4) followed by Zamboni’s fixative (pH 6.9),
14–17 h after the seizure. Brains were post-fixed at 4◦C in the
same fixative for 24 h, cryoprotected in 15 and 30% sucrose
solutions (Vinet et al., 2016) and stored at −80◦C until used.
Horizontal sections of 50 µm were cut using a freezing sliding
microtome (Leica SM2000 R; Leica, Nussloch, Germany). For
immunostaining, sections were washed in Tris-buffered saline
(TBS) and incubated in 3% H2O2 in TBS (30 min) to quench
endogenous peroxidase activity. Following another washing step,
sections were blocked 1 h in TBS containing 2% bovine serum
albumin, 0.3% Triton X-100 (Tx) and 5% normal goat serum.
Sections were then placed at 4◦C with a polyclonal rabbit
anti-PPARγ (Ab209350; Abcam, Cambridge, United Kingdom,
dilution 1:2000, 48 h). After washing, sections were incubated
for 1 h with a biotinylated anti-rabbit secondary antibody
(Vector Laboratories, Burlingame, CA, United States; 1:200),
and later with the avidin-biotin-peroxidase complex (Elite ABC
Kit; Vector Laboratories, Burlingame, CA, United States). The
immunostaining was performed in 0.05% 3,3-diaminobenzidine
tetrahydrochloride for 5 min (DAB, Sigma–Aldrich, Milan, Italy)
and developed by adding 0.03% H2O2. Finally, sections were
washed again in TBS, mounted on gelatin-coated slides and cover
slipped with Eukitt (Eukitt R©, O. Kindler GmbH & Co., Freiburg,
Germany).
Image Analysis
Immunostained sections related to bregma from −8.04 mm to
−5.04 mm for hippocampal CA1 and CA3 regions, and hilus
of the dentate gyrus (DH) were analyzed using an Axioskop
microscope (Carl Zeiss Vision GmbH, Munchen, Germany)
equipped with a 10X objective. Images were digitally captured
by a Sony CCD-IRIS B–W video camera, along the ventrodorsal
direction of the brain (approximately 6–7 serial horizontal
sections separated by 0.5 mm). A mouse brain atlas-C57BL/6J
horizontal was used to assess brain sections. The image analysis
was carried out using the KS300 software (Carl Zeiss Vision
GmbH), as previously described (Biagini et al., 2005; Curia et al.,
2013; Giordano et al., 2015, 2016). PPARγ immunoreactivity was
measured as field area values, corresponding to the addition of
areas of the specific profiles obtained after discrimination from
background staining. Background values in each section were
obtained from areas devoid of specific immunostaining, such as
the angular bundle. All measurements were taken bilaterally and
the final values represent the left–right average.
Double Immunofluorescence
We performed a PPARγ/67-kDa glutamate decarboxylase
(GAD67) qualitative double immunofluorescence to assess
PPARγ expression in interneurons. PPARγ expression
was further evaluated in different interneuron subsets
by PPARγ/parvalbumin (PV), PPARγ/somatostatin-28
(SOM) or PPARγ/vasoactive intestinal peptide (VIP)
qualitative double immunofluorescences. For PPARγ/GAD67
immunofluorescence, sections were washed in TBS at room
temperature and unmasking in sodium citrate at 98◦C and
permeabilized for 1 h in TBS/0.02% Triton X-100 containing
5% normal goat serum. Concerning PPARγ/PV, PPARγ/SOM
and PPARγ/VIP immunofluorescences, sections were washed
in TBS at room temperature and permeabilized for 1 h in
TBS/0.1% Triton X-100 containing 5% normal goat serum. Then,
sections were incubated for 48 h with primary antibodies: rabbit
anti-PPARγ (Ab209350; Abcam, Cambridge, United Kingdom,
dilution 1:50), mouse anti-GAD67 (MAB5406; Chemicon
International, Billerica, MA, United States, dilution 1:200),
mouse anti-PPARγ (E-8, sc-7273; Santa Cruz Biotechnology,
Santa Cruz, CA, United States, dilution 1/50), rabbit anti-PV
(Ab11427; Abcam, Cambridge, MA, United States, dilution
1:2000), rabbit anti-SOM (20089; Immunostar, Hudson, WI,
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United States, dilution 1/1000) and rabbit anti-VIP (20077;
Immunostar, Hudson, WI, United States, dilution 1/500).
Following a washing step in TBS, sections were incubated for
3 h at room temperature with secondary antibodies Alexa Fluor
488-labeled goat anti-mouse antibody (A-11001; Invitrogen,
Carlsbad, CA, United States, dilution 1:500) and Alexa Fluor
594-labeled goat anti-rabbit (A-11012; Invitrogen, Carlsbad, CA,
United States, dilution 1:500). After rinsing sections in TBS,
brain sections were placed on gelatinized glass slides, dried,
and mounted with Mowiol after incubation with DAPI. Images
were acquired using a Leica TCS SP2 (Leica Laser Technik,
Heidelberg, Germany) confocal microscope. All images were
taken using a 40X magnification.
Statistics
Chi-Square test (χ2) was used to compare the percentage (%) of
rats experiencing SE in the various treatment groups. Pairwise
comparisons with Fisher’s exact test (using α correction) were
used to establish differences among groups. Additionally, the
time interval (min) required to develop seizures and SE in the
various groups was analyzed by Kruskal–Wallis test. Dunn’s test
was used for multiple comparisons. One-way analysis of variance
(ANOVA) was used to compare electrographic seizure duration
(sec) in each treatment groups.
The χ2 test was also used to compare mice experiencing
seizures with loss of posture in the various treatment groups.
Again, pairwise comparisons with Fisher’s exact test (using α
correction) were used to establish differences among groups.
Electrocorticographic recordings, analyzed as peak values
of power spectra, were compared using two-way ANOVA,
considering treatments as the between-factor and sessions as
the within-factor. The Holm-Šídák test was used for multiple
comparisons. All statistical analyses were performed using
Sigmaplot 11 (Systat Software, San Jose, CA, United States).
Unless otherwise indicated, results are shown as mean± standard
error of the mean (SEM); p-values lower than 0.05 were
considered as statistically significant.
RESULTS
EP-80317 Reduced the Percentage of
Animals Developing SE after Pilocarpine
Injection
Response to pilocarpine was assessed by expert raters who
directly annotated the motor responses observed during seizure
development according to the modified Racine’s scale (Racine,
1972; Lucchi et al., 2013), and by oﬄine analysis of video-EcoG
recordings. Four (n= 1 saline group, n= 2 EP-80317 group, and
n = 1 GW9662 group) animals died during continuous tonic-
clonic seizures and were excluded from the analysis. Consistently
with previous findings (Biagini et al., 2011), pilocarpine induced
SE in 100% of saline-treated rats. Instead, only 50% of rats
treated with EP-80317 developed SE (p < 0.05 vs. saline-
treated rats, Fisher’s exact test). Additionally, we also found
that the percentages of rats developing SE after pilocarpine
administration in groups treated with GW9662 or GW9662+EP-
80317 (respectively, 83% and 80%) were not significantly different
from that observed in saline-treated rats (Table 1).
GW9662 Accelerated the Development of
Convulsive Seizure and SE in the
Pilocarpine Model
We calculated the time interval required to develop the first
stage 1-3 and stage 4-5 seizure after pilocarpine administration,
as median and interquartile range (IRQ) values. Moreover, we
calculated the time interval required to develop SE (Table 2). No
significant differences were found when comparing the latency
periods of the first stage 1-3 seizure in the various treatment
groups. Instead, the latency periods for developing the first
stage 4-5 seizure were significantly different in GW9662-treated
or GW9662+EP-80317-treated rats compared to, respectively,
saline-treated rats (p < 0.05 for both groups, Dunn’s test) and
the EP-80317 group of treatment (p < 0.05). In addition, the
latency periods for developing SE after the first stage 4-5 seizure
were significantly shorter in GW9662-treated and GW9662+EP-
80317-treated rats compared to saline-treated rats (p< 0.05).
Drug Treatments Did Not Affect Seizure
Duration in Pilocarpine-Treated Rats
We measured the average seizure duration in traces obtained
from ECoG recordings (Figure 1) performed in the various
groups of treatment. No differences were found for animals
treated, respectively, with saline (65.32 ± 8.75 s) or GW9662
(67.15 ± 10.95 s). Although the EP-80317 group presented a
lower seizure duration (45.75 ± 9.24 s), this difference did not
reach a statistically significant level. Mean seizure duration was
also lower (49.91 ± 12.64 s) in GW9662+EP-80317 but, again,
not enough to be statistically relevant.
EP-80317 Transiently Reduced the
Seizure Severity and Duration in the
Repeated 6-Hz Corneal Stimulation
Model
Experimenters first visually monitored seizures induced
through 6-Hz corneal stimulation and their pharmacological
modulations. The first seizure duration was significantly
shorter in mice treated with EP-80317 compared to control
mice (p < 0.05, Holm-Šídák test), thus confirming the
anticonvulsant properties of this molecule (Biagini et al., 2011;
TABLE 1 | Percentage (%) of rats developing status epilepticus (SE) in the various
treatment groups.
Treatments Percentage (%) of rats developing SE
Saline (n = 9) 100%
EP-80317 (EP, n = 8) 50%∗
GW9662 (GW, n = 6) 83%
GW+EP (n = 10) 80%
∗p < 0.05, EP-80317 vs. saline; Fisher’s exact test.
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TABLE 2 | Median and interquartile range values of latency periods for developing seizure and status epilepticus (SE) in the various treatment groups.
Latency (min) Saline EP-80317 (EP) GW9662 (GW) GW+EP
From pilocarpine injection to first stage 1-3 seizure 2.00 (1.75–3.50) 4.00 (3.00–11.75) 3.00 (2.00–4.00) 3.00 (3.00–4.00)
From pilocarpine injection to first stage 4-5 seizure 9.00 (6.75–10.25) 18.00 (8.00–21.25) 3.00 (2.00–4.00)∗§ 3.00 (3.00–4.00)∗§
From pilocarpine injection to SE 17.00 (16.00–18.50) 13.00 (10.75–25.00) 14.00 (11.00–14.50) 16.50 (14.50–21.75)
From first stage 4-5 seizure to SE 8.00 (8.00–10.50) 5.50 (2.75–6.75) 3.00 (2.50–4.50)# 3.50 (3.00–6.50)#
∗p < 0.05, GW9662 vs. saline and GW9662+EP-80317 vs. saline; Dunn’s test. §p < 0.05, GW9662 vs. EP-80317 and GW9662+EP-80317 vs. EP-80317. #p < 0.05,
GW9662 vs. saline and GW9662+EP-80317.
FIGURE 1 | ECoG analysis of seizure duration in the pilocarpine model. Representative epileptiform activity recorded from each treatment group is shown. In
saline-treated and GW9662-treated rats, the seizure duration was similar to those of EP-80317 and GW9662+EP-80317 (GW+EP) groups. LFC, left frontal cortex;
LOC, left occipital cortex; Ref, reference electrode; RFC, right frontal cortex; ROC, right occipital cortex.
Giordano et al., 2016). No differences were noticed by comparing
controls to mice treated with GW9662 alone or prior to EP-80317
(Figure 2A). Similarly seizure severity, defined as the percentage
of mice displaying loss of posture during seizures, was also less
pronounced in the presence of EP-80317 (p < 0.05, EP-80317 vs.
saline in the first session of stimulation; Fisher’s exact test). No
differences were observed by comparing the other groups with
saline-treated mice (Figure 2B).
As expected (Giordano et al., 2015), seizures significantly
shortened by repeating 6-Hz corneal stimulation (p < 0.01,
sessions three and four vs. session one in saline-treated mice;
Holm-Šídák test). Consequently, no differences between mice
treated with saline and EP-80317 were observed from the second
session onward (Figure 2A). Moreover, the severity of seizures
progressed in all groups, including mice treated with EP-80317
(Figure 2B), which confirmed the appearance of resistance to the
effects of EP-80317 (Giordano et al., 2016). Consistently, in the
fourth session of 6-Hz corneal stimulation no differences were
present within the various treatment groups.
EP-80317 Prevented the Increase in
Power Spectra of Seizures Induced by
Repeated 6-Hz Corneal Stimulation
Seizures induced by 6-Hz corneal stimulation and their
pharmacological modulations were further monitored through
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FIGURE 2 | Behavioral changes observed during repeated 6-Hz corneal stimulation. Seizure duration and severity are respectively illustrated in (A,B) for the various
treatment groups. (A) The PPARγ activator EP-80317 significantly reduced the duration of seizures induced by the first 6-Hz corneal stimulation (∗p < 0.05,
EP-80317 vs. saline in the first session of stimulation; Holm-Šídák test). Administering GW9662, a PPARγ blocker, counteracted this effect (GW+EP group). Note
also that seizure duration significantly decreased in control mice at the third and fourth sessions (##p < 0.01, sessions three or four vs. session one in saline-treated
mice; Holm-Šídák test). (B) The seizure severity, evaluated as the percentage of animals displaying postural loss during convulsions, was also significantly affected
by EP-80317 (∗p < 0.05, EP-80317 vs. saline in the first session of stimulation; Fisher’s exact test).
video ECoG recordings. In particular, we compared power
spectra of seizures recorded from frontal (not shown) and
occipital electrodes (Figure 3A). As previously reported
(Giordano et al., 2015), power peaks did not change for
ictal events recorded through frontal cortex electrodes, in
all groups, whereas in the occipital recording we noticed
the presence of an epileptogenic process. In particular, we
found a significant increase in power peaks recorded from
occipital electrodes in the fourth session, both in saline-treated
and GW9662-treated mice (p < 0.01 for saline-treated mice;
p < 0.05 for GW9662-treated mice, session four vs. session
one; Holm-Šídák test; Figure 3B). Conversely, power peaks in
mice treated with EP-80317 did not change from the first to
the fourth session of 6-Hz corneal stimulation, suggesting an
antiepileptogenic effect. This effect was not completely prevented
by administering GW9662 prior to EP-80317, although a
trend was present (p = 0.09). Interestingly, significantly
lower values were found in the fourth session of mice treated
with EP-80317 compared to saline-treated mice (p < 0.05;
Figure 3B).
EP-80317 Significantly Increased PPARγ
Immunoreactivity in the Hippocampus of
Mice Exposed to the First 6-Hz Corneal
Stimulation
We evaluated the effects of repeated exposure to 6-Hz
corneal stimulation on PPARγ immunoreactivity in the stratum
pyramidalis of CA1 (Figure 4), in both stratum pyramidalis and
stratum radiatum/lacunosum-moleculare of CA3 (Figure 5), and
finally in the DH (Figure 6). First, we quantified the changes
occurring after the first and third session of seizure induction
in pyramidal cells of the hippocampus and in mossy cells of
the DH. PPARγ levels were scantily detectable in all sampled
regions of unstimulated control mice. PPARγ immunoreactivity
was not significantly changed in regions of interest of saline-
treated mice. Notably, in animals treated with EP-80317 we
observed a prominent increase in PPARγ levels after the first 6-Hz
corneal stimulation, reaching a statistically significant level in all
the considered regions (p < 0.05 vs. controls, in CA1; p < 0.001
vs. controls and saline-treated mice, in CA3 and DH; Holm-
Šídák test; Figures 4–6). After the third seizure induction, PPARγ
immunoreactivity returned to basal levels in all hippocampal
regions.
To evaluate the response in interneurons, we analyzed
the changes occurring in the stratum radiatum/lacunosum-
moleculare of the CA3 (Table 3). Again, PPARγ levels were barely
detectable in unstimulated control mice and saline-treated mice,
but a significant increase in PPARγ levels was found in mice
treated with EP-80317 after the first 6-Hz corneal stimulation
(p < 0.01 vs. controls; p < 0.05 vs. saline-treated mice, Holm-
Šídák test; Table 3). Consistently, PPARγ levels returned to basal
levels after the third seizure induction.
PPARγ Is Expressed in Different Subsets
of Interneurons
To confirm that PPARγ was expressed in interneurons, we
performed a double immunofluorescence experiment with
PPARγ and GAD67 antibodies. We found that not all
interneurons coexpressed GAD67 and PPARγ immunoreactivity
(Figure 7, top panels). Thus, to assess the subset of interneurons
expressing PPARγ immunoreactivity, we evaluated PPARγ/PV,
PPARγ/SOM and PPARγ/VIP colabeling. PPARγ-positive cells
were frequently observed within PV interneurons (Figure 7, in
which arrows indicate colabeling), and less frequently identified
Frontiers in Pharmacology | www.frontiersin.org 7 September 2017 | Volume 8 | Article 676
fphar-08-00676 September 20, 2017 Time: 15:23 # 8
Lucchi et al. Involvement of PPARγ in EP-80317 Antiseizure Effects
FIGURE 3 | Electrographic changes observed during repeated 6-Hz corneal stimulation. (A) Representative power spectra obtained at session one and four are
illustrated for each treatment group. Note that powers of ictal activity did not significantly change going from first to fourth stimulation in mice treated with EP-80317,
whereas clear alterations were present in all other groups. The inset on the right shows electrographic traces corresponding to power spectra of traces recorded by
the occipital electrodes, after the fourth seizure induction. The gray color is for the first session; the black color is for the fourth session. (B) Mean power spectra of
ictal events obtained through one or four separated 6-Hz corneal stimulation sessions. Histograms show that the power peak of ictal events significantly increased at
the fourth session in saline-treated mice (##p < 0.01, session 4 vs. session 1; Holm-Šídák test) and in mice treated with GW9662 (#p < 0.05, session 4 vs. session
1), but not in mice treated with EP-80317 alone or in combination with GW9662 (GW+EP). Note also that the mean power peak of animals treated with EP-80317
was significantly lower than that of saline-treated mice, at the fourth stimulation (∗p < 0.05, EP-80317 vs. saline in the fourth session of stimulation).
within SOM interneurons. In contrast, PPARγ never colocalized
with VIP in interneurons (Figure 7, in which arrowheads indicate
lack of colabeling).
DISCUSSION
In the present investigation we confirmed that EP-80317 displays
anticonvulsant effects in the pilocarpine model and in the
repeated 6-Hz corneal stimulation model. As major findings
of our investigation, we also demonstrated that GW9662,
an inhibitor of PPARγ activity, is able to counteract the
anticonvulsant effects of EP-80317 in both the animal models,
with the notable exception of the antiepileptogenic properties
disclosed by analyzing the ECoG power spectrum in mice.
We also observed a proconvulsant activity of GW9662 when
analyzing the latency period of stage 4-5 seizures, and the
latency period of SE onset after the first stage 4-5 seizure in
the pilocarpine model. Interestingly, PPARγ immunoreactivity
was transiently increased in pyramidal cells and interneurons
belonging to PV and SOM subclasses, in coincidence with the
anticonvulsant effects of EP-80317 in 6-Hz corneally stimulated
mice.
We previously established that the ghrelin receptor antagonist
EP-80317 is an anticonvulsant in the pilocarpine model (Biagini
et al., 2011), as well as in the repeated 6-Hz corneal stimulation
model (Giordano et al., 2016). We also hypothesized that
its anticonvulsant activity could not be explained by an
involvement of the ghrelin receptor, as we did not observe
any anticonvulsant activity of either the ghrelin receptor
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FIGURE 4 | PPARγ immunoreactivity in the hippocampal CA1 region of mice
treated with saline or EP-80317 and exposed to different sessions of 6-Hz
corneal stimulation. PPARγ immunoreactivity is illustrated in a representative
unstimulated control (Ctrl) mouse and in mice treated with saline (Sal) or
EP-80317 (EP) and respectively exposed to one (Sal-1, EP-1) or three (Sal-3,
EP-3) different sessions of 6-Hz corneal stimulation. Note that PPARγ levels
were significantly increased after the first session in EP-80317 mice only
(◦p < 0.05, EP-1 vs. Ctrl; Holm-Šídák test). Note also that PPARγ levels were
significantly reduced in the third session of EP-80317 mice (##p < 0.01, EP-3
vs. EP-1). Scale bar: 100 µm.
antagonist JMV-2959 (Biagini et al., 2011), nor of ghrelin,
and of the ghrelin receptor agonist JMV-1843 (Biagini et al.,
2011; Lucchi et al., 2013), all administered i.p. 10 min before
injecting pilocarpine. At odds with our data, however, other
investigators consistently showed that ghrelin produces some
anticonvulsant effects in different seizure models (Portelli
et al., 2012a,b). Furthermore, JMV-1843 also was found to
be an anticonvulsant when used at high doses (Coppens
et al., 2016). So, technical reasons, such as the more direct
intracerebroventricular route of ghrelin administration in some
cases (Portelli et al., 2012b), the earlier timing of ghrelin injection
in others (Obay et al., 2007; Lee et al., 2010; Portelli et al.,
2012b), and the different doses of the tested ghrelin receptor
agonist (Coppens et al., 2016) may help in understanding
why ghrelin receptor agonists in our hands did not display
anticonvulsant properties (Biagini et al., 2011; Lucchi et al., 2013).
Alternatively, it could be proposed that different receptors are
involved in the anticonvulsant effects of ghrelin and its related
peptides.
EP-80317 was found to activate PPARγ, as well as its cascade
in apolipoprotein E-deficient mice (Bujold et al., 2009, 2013;
Bulgarelli et al., 2009). Although PPARγ was mainly localized
in the liver and in adipocytes, in which it was characterized
for its role in metabolism regulation (Demers et al., 2008; Li
et al., 2014; Gorga et al., 2017), it was also found that PPARγ
agonists such as rosiglitazone or pioglitazone display antiseizure
FIGURE 5 | PPARγ immunoreactivity in the hippocampal CA3 region of mice
treated with saline or EP-80317 and exposed to different sessions of 6-Hz
corneal stimulation. PPARγ immunoreactivity is illustrated in a representative
unstimulated control (Ctrl) mouse and in mice treated with saline (Sal) or
EP-80317 (EP) and respectively exposed to one (Sal-1, EP-1) or three (Sal-3,
EP-3) different sessions of 6-Hz corneal stimulation. Note that PPARγ levels
were significantly increased after the first session in EP-80317 mice only
(◦◦◦p < 0.001, EP-1 vs. Ctrl; Holm-Šídák test). In EP-80317 mice, PPARγ
levels were also significantly different from saline-treated mice (∗∗∗p < 0.001,
EP-1 vs. Sal-1 in CA3). Note also that PPARγ levels were significantly reduced
in the third session of EP-80317 mice (###p < 0.001, EP-3 vs. EP-1). Scale
bar: 100 µm.
effects (Adabi Mohazab et al., 2012; Hong et al., 2013). It
has also been proposed that PPARγ plays a key role in the
antiseizure effects of cannabinoid agonists (Payandemehr et al.,
2015), as well as in the anticonvulsant effects of the ketogenic
diet (Jeong et al., 2011; Simeone et al., 2017). In agreement
with these suggestions, our data support the involvement of
PPARγ in the anticonvulsant effects of EP-80317. Consistently,
by inhibiting PPARγ with the antagonist GW9662, the effects
of rosiglitazone on seizure-like activity induced by Mg2+-free
medium in hippocampal slices were partially prevented (Wong
et al., 2015). In line with these in vitro studies, the effects
of EP-80317 were counteracted by GW9662 in our in vivo
experiments and, additionally, we have identified a proconvulsant
effect of GW9662 in the pilocarpine model. Indeed, as GW9662
produced a decrease in the latency period of tonic-clonic seizures
and accelerated the onset of SE, a question arises on whether
the GW9662 and EP-80317 combination resulted in the simple
summation of their independent pro/anticonvulsant effects or
not, at least in the pilocarpine model.
The suggested ability to modulate seizures of PPARγ could be
explained by the fact that this nuclear receptor is also expressed
in peripheral immune cells, microglia, and neurons (Moreno
et al., 2004; Bujold et al., 2009; Warden et al., 2016). Especially
by acting on immune cells, PPARγ exerts a negative modulation
of macrophages and microglia reactivity (Moreno et al., 2004;
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FIGURE 6 | PPARγ immunoreactivity in the hilus of dentate gyrus (DH) of mice
treated with saline or EP-80317 and exposed to different sessions of 6-Hz
corneal stimulation. PPARγ immunoreactivity is illustrated in a representative
unstimulated control (Ctrl) mouse and in mice treated with saline (Sal) or
EP-80317 (EP) and respectively exposed to one (Sal-1, EP-1) or three (Sal-3,
EP-3) different sessions of 6-Hz corneal stimulation. Note that PPARγ levels
were significantly increased after the first session in EP-80317 mice only
(◦◦◦p < 0.001, EP-1 vs. Ctrl; Holm-Šídák test). PPARγ levels were also
significantly different from saline-treated mice (∗∗∗p < 0.001, EP-1 vs. Sal-1).
Note also that PPARγ levels were significantly reduced in the third session of
EP-80317 mice (###p < 0.001, EP-3 vs. EP-1). Scale bar: 100 µm.
Bujold et al., 2009; Warden et al., 2016), resulting in an anti-
inflammatory action in the nervous tissue (Jeong et al., 2011).
This effect may be important as several lines of evidence suggest
that leukocytes and microglia are critical in establishing the onset
of SE in the pilocarpine model (Fabene et al., 2008; Vezzani et al.,
2015; Vinet et al., 2016). In particular, treatment with antibodies
against leukocyte α4 integrin, which is involved in inflammation,
successfully prevented the onset of SE in pilocarpine-treated
mice (Fabene et al., 2008). Additional evidences indicate that
inflammation is required to establish the SE in pilocarpine-
treated rodents (Marchi et al., 2009; Vezzani et al., 2015).
Overall, these findings suggest that EP-80317 activation of the
PPARγ pathway in immune cells (Bujold et al., 2009, 2013;
Bulgarelli et al., 2009) may have contributed to prevent the
SE in pilocarpine-treated rats. However, we cannot rule out
the possibility that other ghrelin analogs could share the same
mechanism found for EP-80317. Indeed, further experiments are
required to establish if PPARγ may mediate the anticonvulsant
effects of other ghrelin receptor agonists or antagonists.
The effects of EP-80317 on PPARγ could be dependent on
a direct modulation of the neuronal activity. As a matter of
fact, EP-80317 markedly increased PPARγ immunoreactivity in
hippocampal pyramidal neurons and also in interneurons of 6-
Hz corneally stimulated mice. It is interesting to notice that
we have identified PPARγ in interneurons and described its
expression in different interneuron subpopulations for the first
TABLE 3 | EP-80317 (EP) significantly increased PPARγ immunoreactivity in
interneurons within the CA3 stratum radiatum/lacunosum-molecolare of mice
exposed to the first 6-Hz corneal stimulation (EP-1), but not in mice exposed to
the third stimulation (EP-3), compared to saline-treated mice (Sal) and controls
(Ctrl).
Treatment groups Field area (mm2) mean values SEM
Ctrl (n = 4) 0.016 0.0016
Sal-1 (n = 5) 0.020 0.0021
EP-1 (n = 5) 0.035◦◦∗ 0.0055
Sal-3 (n = 7) 0.018 0.0009
EP-3 (n = 6) 0.010### 0.0018
∗p < 0.05, EP-1 vs. Sal-1; Holm-Šídák test; ◦◦p < 0.01, EP-1 vs. Ctrl;
###p < 0.001, EP-3 vs. EP-1.
time. Recently, the role of interneurons in seizure initiation
and propagation has become more controversial (de Curtis and
Avoli, 2016). In particular, the different interneuron subclasses
were suggested to play specific roles in modulating seizures
(Khoshkhoo et al., 2017). Here, we found that PV and SOM
but not VIP interneurons expressed PPARγ and, thus, were
probably involved in the anticonvulsant effects of EP-80317.
Interestingly, optogenetic inhibition of VIP interneurons affected
both the seizure threshold and duration, whereas PV and
SOM interneuron inhibition apparently reduced only the seizure
duration (Khoshkhoo et al., 2017). According to these data, it
is possible that the effects on seizure duration observed with
EP-80317 in 6-Hz stimulated mice could be partly mediated
by modulation of PV and SOM interneurons. It could also
be of interest to evaluate other PPARγ modulators, such as
rosiglitazone or pioglitazone, in the pilocarpine model and,
especially, in the repeated 6-Hz corneal stimulation model to
examine their effects in exactly the same experimental conditions
in which we characterized EP-80317.
Although all the EP-80317 anticonvulsant effects were
counteracted by GW9662, a notable exception was found
by analyzing the ECoG power spectra of 6-Hz corneally
stimulated mice. In particular, we observed that the power of
ECoG recordings increased significantly in saline-treated and
GW9662-treated mice, but not in mice receiving EP-80317 or
GW9662+EP-80317. These findings suggest that the already
proposed antiepileptogenic activity of EP-80317 (Giordano et al.,
2016) may be independent of PPARγ activation. This hypothesis
is in line with the time course of PPARγ induction in the
hippocampus, which has been characterized by a transient
increase at the first session of seizure induction returning to basal
levels at the third session. So, PPARγ was presumably restored at
basal levels when the effect of EP-80317 on the power of ECoG
recordings was still present. Although we could not establish if
this last finding was related to antagonism at the ghrelin receptor,
it was certainly worth to further investigate this pharmacological
activity of EP-80317 in view of the well-recognized need of
antiepileptogenic drugs to prevent the appearance of epilepsy in
subjects exposed to this risk, as in the case of patients which
develop SE and, for this reason (Santamarina et al., 2015), may
become affected by epilepsy.
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FIGURE 7 | Double immunofluorescence of interneurons expressing PPARγ. Photomicrographs illustrating co-labeling with glutamate decarboxylase 67 (GAD67,
green) and PPARγ (red) in CA1 of a representative mouse are shown in top panels. Double immunofluorescence revealed the co-expression of GAD67 and PPARγ in
some (arrows), but not all interneurons (arrowhead point to a PPARγ negative interneuron). Scale bar: 50 µm. Photomicrographs illustrating co-labeling of PPARγ
(green) and parvalbumin (PV, red), somatostatin (SOM, red), or vasoactive intestinal peptide (VIP, red) in the hippocampus of mice exposed to repeated 6-Hz corneal
stimulation are sequentially shown from the second row to bottom. Note that double immunofluorescence revealed the co-labeling of PPARγ/PV in CA3,
PPARγ/SOM in the hilus of dentate gyrus (DH) (arrows), but not PPARγ/VIP in CA1 (arrowhead). Scale bar: 50 µm.
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